中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 1
Jan.  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(1): 86-90

Prognosis of acute-on-chronic liver failure caused by hepatitis recurrence after withdrawal of nucleos(t)ide analogues in chronic hepatitis B patients with different HBeAg status

DOI: 10.3969/j.issn.1001-5256.2022.01.013
  • 1.

    Department of Infectious Diseases, Shaoxing People's Hospital, Shaoxing, Zhejiang 312000, China

  • 2.

    Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital of Nanchang University, Key Laboratory of Liver Regeneration of Jiangxi Province, Nanchang 330006, China

  • 3.

    Department of Science and Technology, The First Affiliated Hospital of Nanchang University, Nanchang 330006, China

  • 4.

    Department of Hepatology, Ganzhou Fifth People's Hospital, Ganzhou, Jiangxi 341099, China

Research funding:

Science and Technology Plan (guiding plan) Project of Jiangxi Provincial Health Commission (202140689);

Science and Technology Plan Project of Jiangxi Provincial (20212BAG70022);

Teaching Reform Project of Nanchang University (NCUJGLX-2020-166-162)

  • Received Date: 2021-09-28
  • Accepted Date: 2021-12-01
  • Published Date: 2022-01-20
    Abstract
  •   Objective  To investigate the difference in the prognosis of hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) caused by hepatitis recurrence after withdrawal of nucleos(t)ide analogues (NUC) and possible causes in HBeAg-positive versus HBeAg-negative chronic hepatitis B (CHB) patients.  Methods  A total of 108 CHB patients with HBV-ACLF caused by withdrawal of NUC who were admitted to The First Affiliated Hospital of Nanchang University from January 2017 to December 2018 were enrolled, and according to HBeAg status, these patients were divided into HBeAg-positive group with 57 patients and HBeAg-negative group with 51 patients. The two groups were compared in terms of sex, age, clinical manifestation, signs, levels of total bilirubin, direct bilirubin, alanine aminotransferase, aspartate aminotransferase, prothrombin time, activated partial thromboplastin time, prothrombin time/international normalized ratio, and HBV DNA quantification on admission, complications (including hepatic encephalopathy, hepatorenal syndrome, and spontaneous bacterial peritonitis), and prognosis of HBV-ACLF. In addition, 48 CHB patients with continuous NUC antiviral therapy for > 2 years and HBV DNA < 20 IU/mL were enrolled, and the serum level of HBV pgRNA was measured to investigate the possible causes of the difference in the prognosis of HBV-ACLF between the patients with different HBeAg statuses. The two-independent-samples t test was used for comparison of normally distributed continuous data between two groups, and the Kruskal-Wallis H test was used for comparison of non-normally distributed continuous data between two groups; the chi-square test was used for comparison of categorical data.  Results  For the 108 patients with HBV-ACLF caused by drug withdrawal and recurrence, the HBeAg-positive group had an improvement rate of 49.1% and the HBeAg-negative group had an improvement rate of 74.5%. The HBeAg-negative group had a significantly higher improvement rate than the HBeAg-positive group (χ2=2.811, P=0.006). The HBeAg-positive group had a significantly higher level of HBV DNA than the HBeAg-negative group on admission (t=-3.138, P=0.002). For the 48 CHB patients who achieved virologic response after long-term antiviral therapy, the HBeAg-positive group had a significantly higher HBV pgRNA load than the HBeAg-negative group (H=2.814, P=0.049).  Conclusion  Compared with the HBeAg-positive CHB patients, HBeAg-negative CHB patients have a significantly better improvement rate of HBV-ACLF caused by hepatitis recurrence after withdrawal of NUC antiviral therapy. The difference in baseline HBV pgRNA level may be associated with the difference in the prognosis of HBV-ACLF in patients with different HBeAg statuses.

     

    • FullText(HTML)
  • loading
    • References(15)
  • [1]
    ZHAO RH, SHI Y, ZHAO H, et al. Acute-on-chronic liver failure in chronic hepatitis B: An update[J]. Expert Rev Gastroenterol Hepatol, 2018, 12(4): 341-350. DOI: 10.1080/17474124.2018.1426459.
    [2]
    Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure(2018)[J]. J Clin Hepatol, 2019, 35(1): 38-44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.

    中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版)[J]. 临床肝胆病杂志, 2019, 35(1): 38-44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.
    [3]
    PETERSEN J, BUTI M. Considerations for the long-term treatment of chronic hepatitis B with nucleos(t)ide analogs[J]. Expert Rev Gastroenterol Hepatol, 2012, 6(6): 683-693; quiz 694. DOI: 10.1586/egh.12.52.
    [4]
    SHOUVAL D, LAI CL, CHANG TT, et al. Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: The case for continuous antiviral therapy[J]. J Hepatol, 2009, 50(2): 289-295. DOI: 10.1016/j.jhep.2008.10.017.
    [5]
    HU GF, LI XP, WU ZP, et al. Clinical features of acute-on-chronic liver failure induced by withdrawal of nucleos (t) ide analogues[J]. J Clin Hepatol, 2017, 33(7): 1320-1323. DOI: 10.3969/j.issn.1001-5256.2017.07.023.

    胡高飞, 李小鹏, 吴振平, 等. 停用核苷和核苷酸类药物抗HBV后诱发慢加急性肝衰竭的临床特征[J]. 临床肝胆病杂志, 2017, 33(7): 1320-1323. DOI: 10.3969/j.issn.1001-5256.2017.07.023.
    [6]
    TAN M, BHADORIA AS, CUI F, et al. Estimating the proportion of people with chronic hepatitis B virus infection eligible for hepatitis B antiviral treatment worldwide: A systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2021, 6(2): 106-119. DOI: 10.1016/S2468-1253(20)30307-1.
    [7]
    SU TH, KAO JH. Improving clinical outcomes of chronic hepatitis B virus infection[J]. Expert Rev Gastroenterol Hepatol, 2015, 9(2): 141-154. DOI: 10.1586/17474124.2015.960398.
    [8]
    GUO W, LI WN, NING Q. Definition and natural history of severe hepatitis B[J]. J Pract Hepatol, 2016, 19(3): 264-265. DOI: 10.3969/j.issn.1672-5069.2016.03.003.

    郭威, 李维纳, 宁琴. 乙型肝炎重症化的概念及自然史[J]. 实用肝脏病杂志, 2016, 19(3): 264-265. DOI: 10.3969/j.issn.1672-5069.2016.03.003.
    [9]
    YU Y, WANG J, LI G, et al. Nucleos(t)ide analogue interruption: Alternative approach to intrahepatic set point for spontaneous control of HBV replication?[J]. J Hepatol, 2018, 68(3): 609-610. DOI: 10.1016/j.jhep.2017.09.026.
    [10]
    LIU JY, DANG DJ, LU ZN, et al. Clinical observation on Tenofovir Disoproxil treating the poor effect of Lamivudine resistance combined with Adefovir Dipivoxil[J. China Med Herald, 2020, 17(15): 127-130. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY202015034.htm

    刘军英, 党殿杰, 路振宇, 等. 替诺福韦酯治疗拉米夫定耐药联合阿德福韦酯效果不佳的临床观察[J]. 中国医药导报, 2020, 17(15): 127-130. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY202015034.htm
    [11]
    Chinese Society of Infectious Diseases, Chinese Medical Association, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.

    中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
    [12]
    MAK LY, SETO WK, FUNG J, et al. Novel developments of hepatitis B: Treatment goals, agents and monitoring tools[J]. Expert Rev Clin Pharmacol, 2019, 12(2): 109-120. DOI: 10.1080/17512433.2019.1567327.
    [13]
    CAI Y, PAN L, LIN B, et al. Relationship between Treg/Th17 balance and changes in HBeAg among HBeAg-positive chronic hepatitis B patients receiving entecavir therapy[J]. Int J Virol, 2020, 27(5): 407-411. DOI: 10.3760/cma.j.issn.1673-4092.2020.05.013.

    蔡云, 潘良, 林斌, 等. 恩替卡韦治疗HBeAg阳性慢性乙型肝炎患者外周血Treg/Th17平衡与HBeAg的变化[J]. 国际病毒学杂志, 2020, 27(5): 407-411. DOI: 10.3760/cma.j.issn.1673-4092.2020.05.013.
    [14]
    BIAN DD, ZHENG SJ. Role of serum hepatitis B virus RNA quantification in guiding antiviral therapy for chronic hepatitis B[J]. J Clin Hepatol, 2020, 36(8): 1838-1841. DOI: 10.3969/j.issn.1001-5256.2020.08.035.

    卞丹丹, 郑素军. 血清HBV RNA定量在指导慢性乙型肝炎抗病毒治疗过程中的作用[J]. 临床肝胆病杂志, 2020, 36(8): 1838-1841. DOI: 10.3969/j.issn.1001-5256.2020.08.035.
    [15]
    LIU BX, ZHANG LL, ZHANG WF. Changes of hepatitis B core antigen-specific cytotoxic T lymphocytes in chronic hepatitis B patients during antiviral treatment and relapse after withdrawal of treatment[J]. Chin J Infect Dis, 2016, 34(8): 480-484. DOI: 10.3760/cma.j.issn.1000-6680.2016.08.006.

    刘碧霞, 张伦理, 张文峰. 慢性乙型肝炎患者抗病毒治疗与停药复发后体内乙型肝炎核心抗原特异性T淋巴细胞变化[J]. 中华传染病杂志, 2016, 34(8): 480-484. DOI: 10.3760/cma.j.issn.1000-6680.2016.08.006.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (802) PDF downloads(69) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return